Alarm as FDA Fast-tracks First Antipsychotic for Dementia Agitation
The BMJ investigative unit has raised serious questions about the harm-benefit balance of the new drug Rexulti. The US Food and Drug Administration (FDA) has fast tracked the approval of Rexulti, the first antipsychotic for […]